600
Participants
Start Date
November 30, 2017
Primary Completion Date
July 12, 2018
Study Completion Date
July 12, 2018
Fulvestrant for Injectable Suspension
Test drug is administered as a single 5mL intramuscular injection in the right or left dorsogluteal muscle area
Faslodex (Reference)
Reference drug is administered as two 5mL intramuscular injections, one in each of the right and left dorsogluteal muscle areas
Avail Clinical Research, LLC, DeLand
Orlando Clinical Research Center, Orlando
Clinical Pharmacology of Miami, LLC, Miami
Quotient Sciences, Miami
Advanced Pharma CR, LLC, Miami
New Orleans Center for Clinical Research, Knoxville
New Horizon Clinical Research, Cincinnati
Worldwide Clinical Trials, San Antonio
Optimal Research, LLC, Austin
Clinical Research Consortium, Las Vegas
Collaborative Neuroscience Network, LLC, Long Beach
Hassman Research Institute, Berlin
Lead Sponsor
Eagle Pharmaceuticals, Inc.
INDUSTRY